```html

Human papillomavirus infection (HPV) – Complete Medical Guide

Overview

Human papillomavirus (HPV) is a group of more than 200 related viruses that infect the skin and mucous membranes. While most HPV infections are asymptomatic and resolve on their own, certain types can cause genital warts or lead to cancers of the cervix, vagina, vulva, penis, anus, and oropharynx (throat).

• Prevalence: The Centers for Disease Control and Prevention (CDC) estimates that ~79 million Americans are currently infected, and about 14 million new infections occur each year in the United States alone.<sup>1</sup>
• Who it affects: Both men and women can be infected. The virus is most common among sexually active individuals ages 15‑29, but it can affect anyone who is sexually active, including people who have sex with men (MSM) and those who have never had penetrative sex (through skin‑to‑skin contact).
• Global burden: According to the World Health Organization (WHO), HPV is responsible for nearly 5% of all cancers worldwide, with cervical cancer accounting for 85% of HPV‑related cancer cases.<sup>2</sup>

Symptoms

Most HPV infections produce no symptoms and clear spontaneously within 1‑2 years. When symptoms occur, they depend on the HPV type.

Genital warts (low‑risk HPV types 6 & 11)

• Soft, flesh‑colored or gray growths on the vulva, vagina, cervix, penis, scrotum, or anal area.
• Often appear as small bumps or a cluster that resembles a cauliflower.
• May be itchy, painful, or bleed when irritated.

Cervical dysplasia (precancerous changes)

• No outward symptoms; detected by abnormal Pap test or HPV DNA test.

High‑risk HPV cancers

• Cervical cancer: Abnormal vaginal bleeding, pelvic pain, pain during intercourse.
• Anal cancer: Bleeding, pain, lump, or changes in bowel habits.
• Oropharyngeal cancer: Persistent sore throat, difficulty swallowing, ear pain, lumps in the neck.
• Penile or vulvar cancer: Non‑healing sores, itching, or lumps.

Rare presentations

• Respiratory papillomatosis – warty growths in the airway causing hoarseness or breathing difficulties (usually congenital or linked to maternal HPV).

Causes and Risk Factors

HPV is a DNA virus spread primarily through direct skin‑to‑skin contact. It does not require intercourse; any genital, anal, or oral contact can transmit the virus.

Primary cause

• Transmission of infected epithelial cells during sexual activity (vaginal, anal, oral).
• Contact with contaminated surfaces (e.g., towels, razors) is theoretically possible but extremely rare.

Risk factors

• Sexual behavior: Early onset of sexual activity, multiple sexual partners, and having a partner who has other partners increase exposure.<sup>3</sup>
• Immunosuppression: HIV infection, organ transplantation, or chronic corticosteroid use reduces clearance of the virus.
• Smoking: Tobacco exposure impairs local immune response and doubles the risk of cervical dysplasia.
• Co‑infection with other STIs: Particularly chlamydia and herpes simplex virus, which can disrupt mucosal barriers.
• Pregnancy: Hormonal changes can promote wart growth.
• Lack of vaccination: Persons who have not received the HPV vaccine are at higher risk.

Diagnosis

Diagnosis depends on the manifestation (warts vs. dysplasia vs. cancer) and patient sex.

Screening tests

• Pap smear (Pap test): Cytology of cervical cells every 3 years for women 21‑65; detects abnormal cell changes.
• HPV DNA test: Detects high‑risk HPV types in cervical samples. Recommended concurrently with Pap test for women ≥30 or as a reflex test after abnormal Pap.

Diagnostic procedures for warts

• Visual inspection by a clinician; no lab test needed.
• Biopsy if the lesion is atypical or does not respond to treatment.

Evaluation of suspected cancer

• Colposcopy with directed biopsy for cervical abnormalities.
• Anal or oropharyngeal examination with imaging (MRI, CT, PET) and biopsy when cancer is suspected.

Laboratory confirmation

HPV genotyping (e.g., PCR‑based assays) can identify specific high‑risk strains, useful for research and in certain clinical scenarios (e.g., persistent infection after treatment).

Treatment Options

HPV infection itself often has no cure; treatment targets the disease manifestations and reduces transmission.

Genital warts

• Topical agents: Imiquimod 5% cream (immune response modifier), podofilox solution, or sinecatechins (green tea extract).
• Procedural removal: Cryotherapy (liquid nitrogen), electrocautery, laser therapy, or surgical excision.
• Patients should avoid sexual activity or use condoms until warts are cleared.

Precancerous cervical lesions

• Watchful waiting: Low‑grade lesions (CIN 1) often regress spontaneously; follow‑up Pap/HPV testing at 12 months.
• Ablative therapies: Cryotherapy, Loop Electrosurgical Excision Procedure (LEEP), or cold‑knife conization for CIN 2/3.
• Post‑procedure surveillance every 6‑12 months for up to 2 years.

HPV‑related cancers

• Surgery (e.g., hysterectomy, tonsillectomy) combined with radiotherapy and/or chemotherapy depending on stage.
• Targeted therapies (e.g., pembrolizumab) are approved for recurrent/metastatic head‑and‑neck cancers linked to HPV.

Adjunctive measures

• Smoking cessation improves clearance and reduces progression.
• Immune‑supportive lifestyle (balanced diet, adequate sleep, stress reduction).

Living with Human papillomavirus infection (HPV)

Most people live normal lives with HPV. Practical tips can ease anxiety and support health.

• Stay informed: Know which HPV type you have (low vs. high risk) and understand its natural history.
• Regular follow‑up: Adhere to screening schedules (Pap/HPV test) even if you feel well.
• Safe sex practices: Use condoms or dental dams every time; they reduce but do not eliminate risk.
• Manage warts discreetly: Keep the area clean, avoid picking, and follow treatment instructions.
• Emotional health: Seek counseling or support groups if you feel stigmatized; HPV is extremely common.
• Vaccination for partners: Even if you are already infected, vaccinating a partner can protect them from other HPV types.
• Inform sexual partners: Disclosure encourages shared responsibility and appropriate testing.

Prevention

Vaccination

The most effective preventive measure is the prophylactic HPV vaccine.

• Available vaccines (US/Europe): Gardasil 9 protects against nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, 58).
• Recommended for boys and girls at ages 11‑12; can be started at age 9.
• Catch‑up vaccination is advised up to age 26 for those not previously vaccinated; shared‑decision making may extend to ages 27‑45.
• Vaccination reduces risk of cervical cancer by up to 90% and genital warts by >90%.<sup>4</sup>

Behavioral strategies

• Limit number of sexual partners and practice mutual monogamy.
• Consistent condom and dental‑dam use.
• Avoid smoking and excessive alcohol.
• Regular STI testing; treat co‑infections promptly.

Community and public‑health measures

• School‑based vaccination programs.
• Public education campaigns emphasizing that HPV is common and preventable.

Complications

If left untreated, high‑risk HPV can progress to serious disease.

• Cervical cancer: 4th most common cancer in women worldwide; 311,000 deaths annually.<sup>2</sup>
• Anal cancer (higher in MSM and HIV‑positive individuals).
• Oropharyngeal squamous cell carcinoma – now the most common HPV‑related cancer in the U.S.
• Recurrent respiratory papillomatosis – may require multiple surgeries and can be life‑threatening.
• Emotional and psychosocial burden from chronic warts or cancer diagnosis.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. “Genital HPV Prevalence.” 2023. https://www.cdc.gov/std/hpv/stats.htm
2. World Health Organization. “Human papillomavirus (HPV) and cervical cancer.” 2022. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
3. American Sexual Health Association. “HPV and Sexual Behavior.” 2021. https://www.ashasexualhealth.org/hpv-and-sexual-behavior/
4. Mayo Clinic. “HPV vaccine: What you need to know.” 2023. https://www.mayoclinic.org/vaccines/hpv
5. National Cancer Institute. “HPV‑Associated Cancer Statistics.” 2024. https://www.cancer.gov/types/cervical/hpvs

```